Valuation
- Market cap
- 1,232,702,000
- Revenue TTM
- $0
- Net income TTM
- $-73,210,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 783,700
- Avg volume
- 1,123,940
- Day's range
- $47.98 – $48.00
- Shares out
- 25,692,000
- Stochastic %K
- 83%
- Beta
- 2.27
- Analysts
- Hold
- Price target
- $48.67
Company profile
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines an...
Show more
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 481 9832
- Website
- https://www.tourmalinebio.com
- Address
- 27 West 24th Street, Suite 702, New York, United States
Latest news
No headlines yet.
